Date of last update: October 19, 2026.
Preamble
This website (the “Site”) is published by GenSight Biologics S.A. (“GenSight Biologics”), whose contact details appear in the Legal Notice. Access to and use of the Site are subject to these terms of use (the “Terms”) and to applicable law. By continuing to browse the Site, you acknowledge that you have read the Terms. If you do not accept them, please do not use the Site.
The processing of personal data is described in the Privacy Policy and the Cookie Policy, which can be accessed from every page of the Site.
1. Nature of the information published
1.1 General information. The content of the Site is provided for information purposes only. It relates to GenSight Biologics, its research and development activities and, more generally, certain medical conditions and the state of science.
1.2 Product candidates in development. GenSight Biologics is developing product candidates (drug product or combined product) that are currently at the research and development stage. No GenSight Biologics product is authorized or marketed in any country. The safety and efficacy of the product candidates mentioned on the Site have not been established and will be established only following completion of the applicable regulatory evaluation procedures. Nothing on the Site should be construed as a statement, guarantee or promise that these product candidates will obtain marketing authorization or will ever become available.
1.3 No promotional purpose. The Site is not intended to promote, recommend or propose the use of any medicinal product, combined product or drug candidate, or to encourage participation in a clinical trial. The press releases and presentations in the “Investors” section are intended for investors and do not constitute communication directed at patients or healthcare professionals about the product candidates.
1.4 No medical advice. The information on the Site does not constitute medical advice, a diagnosis or a therapeutic recommendation, and does not replace consultation with a physician or other healthcare professional. Please never delay or discontinue treatment because of information read on the Site. In an emergency, contact the emergency services (in France, dial 15 or 112).
1.5 Exceptional access. GenSight Biologics does not provide access to its drug candidate other than through authorized clinical trials and the exceptional access schemes provided by law. Any request in this respect must be sent by a healthcare professional to medinfo@gensight-biologics.com, with no guarantee of a favorable response.
1.6 Forward-looking statements. The Site may contain forward-looking statements relating in particular to research and development programs, clinical trial timelines, regulatory prospects, cash position and financing horizon, or the strategy of GenSight Biologics. These statements are based on the assumptions, estimates and information available to GenSight Biologics at the date of their publication. They are not guarantees of future performance and are subject to risks and uncertainties, including scientific, clinical, regulatory, intellectual property and financing risks, described in the most recent universal registration document (document d’enregistrement universel) available in the Regulated Information section of the Site and any amendments thereto, as well as in the half-year financial report and the press releases of GenSight Biologics, available in the Regulated Information section of the Site and at www.amf-france.org. Actual results and events may differ materially. Subject to its legal and regulatory obligations, GenSight Biologics has no obligation to update these statements.
1.7 Third-party content. The Site may contain expert opinions, press excerpts or scientific references from third parties. They reflect only the views of their authors. Links to third-party websites are provided for information only, and GenSight Biologics has no control over their content.
2. “Investors” section
The shares of GenSight Biologics are admitted to trading in the regulated market of Euronext Paris (ISIN code FR0013183985, ticker SIGHT).
2.1 Nature of the information. The information in the “Investors” section is provided for information purposes only. It does not constitute a public offer or a solicitation to buy, subscribe for or sell securities of GenSight Biologics, nor investment advice, nor a personalized recommendation. Any investment decision should be made considering all the public information of GenSight Biologics and, where appropriate, after advice from an independent financial adviser. Investing in a development-stage biotechnology company involves a high degree of risk, up to and including the loss of the entire amount invested. The Site does not constitute a prospectus or a public offer of securities within the meaning of Regulation (EU) 2017/1129.
2.2 Regulated information and published documents. The Site reproduces certain documents (press releases, financial reports, documents filed with the AMF). The regulated information of GenSight Biologics is effectively and fully disseminated by a professional disseminator in accordance with the AMF General Regulation and posted in the Regulated Information section of the Site, where it remains accessible for at least five years. The reference version is the one disseminated by that disseminator. Each document is up to date as of the date it bears, and historical archives are not updated.
2.3 Market data. Share prices and market data are provided by Euronext, with substantial delays, for indicative purposes only. GenSight Biologics does not guarantee their accuracy or completeness.
2.4 Analysts. The list of analysts covering GenSight Biologics is provided for information only. Analyses and consensus estimates are prepared under the sole responsibility of their authors. GenSight Biologics does not validate, review or endorse them.
2.5 Geographic restrictions. The information in this section is not intended for persons located in any country where its distribution would be contrary to local regulations, for example the United States, Canada, Australia, Japan and the United Kingdom. It is the responsibility of each person to find out about and comply with the applicable restrictions. The securities of GenSight Biologics have not been registered under the U.S. Securities Act of 1933.
2.6 No selective disclosure. GenSight Biologics does not disclose inside information in response to individual requests. Exchanges with investor relations cannot give rise to the disclosure of non-public information. Contact: investor-relations@gensight-biologics.com.
3. Information on clinical trials
The “Clinical Trials” page provides general information on the clinical trials of GenSight Biologics. It does not constitute a solicitation to participate, a recommendation to enroll, or information on the safety or efficacy of the product candidates, which are investigational and have not been authorized.
Each trial is conducted after authorization by the competent authorities and a favorable opinion from the ethics committee, in accordance with applicable regulations. It is identified by its registration number (NCT) in the public registry ClinicalTrials.gov. Participation is voluntary and subject to the eligibility criteria of the protocol, as assessed by the investigator physician.
If you think you may be eligible, please talk to your physician, who may contact medinfo@gensight-biologics.com. Do not send health data through the Site. Financial information on these trials is provided in the “Investors” section.
4. Reporting adverse events and safety concerns
The Site is not a channel for collecting health data and is not an emergency service. Do not describe your medical situation on the Site.
- If you are taking part in a clinical trial and experience an adverse event, contact your physician investigator or the trial team without delay, following the instructions you were given.
- If you are a healthcare professional or an investigator and wish to report a safety event, use the dedicated contact: gensightsafety@voisinconsulting.com.
- If you nevertheless send us information of this kind, GenSight Biologics may be required to process it and to transmit it to the competent authorities, in accordance with applicable regulations.
5. Intellectual property
5.1 Rights of GenSight Biologics. The Site and its content (texts, still or animated images, graphics, icons, videos, sounds, databases, structure, trademarks, names, logos, domain names and any other element) are the property of GenSight Biologics or of third parties that have granted it the necessary rights and are protected by intellectual property law. The trademarks and logos of GenSight Biologics are protected trademarks, unless otherwise stated.
5.2 Permitted use. You may view the Site and reproduce extracts from it for strictly personal, non-commercial and not-for-profit use, provided that you do not remove any proprietary notice, do not modify the content and do not redistribute it. Any other use (reproduction, communication to the public, adaptation, translation, extraction or re-use of databases, etc.) requires the prior written consent of GenSight Biologics, subject to the exceptions provided for by law. Short quotations with attribution of the source remain permitted within the limits of the law.
5.3 Text and data mining. Pursuant to Article L122-5-3 of the French Intellectual Property Code, GenSight Biologics expressly reserves the right to opt out of the extraction and mining of text and data from the content of the Site, including for the purpose of training artificial intelligence systems, without prior authorization.
5.4 Third-party trademarks. The trademarks and names of third parties cited belong to their respective owners, and their mention implies no link or partnership, unless otherwise stated.
6. Hyperlinks
Simple links to the home page or to pages of the Site are permitted, provided that they do not create confusion as to the origin of the content, do not damage the image or trademarks of GenSight Biologics, and do not use framing techniques or misleading reproduction of the content. GenSight Biologics may request the removal of any link that does not comply with these principles.
7. Unsolicited communications and proposals
7.1 No confidential or sensitive data. The forms, contact addresses and other means of communication on the Site are not designed to receive confidential information, trade secrets, health data or sensitive personal data. Please do not send any.
7.2 Collaboration proposals. If you wish to propose a collaboration, partnership, technology or idea, please contact GenSight Biologics at infos@gensight-biologics.com without disclosing any confidential information. Investor relations is not a channel for submitting collaboration proposals. A confidentiality agreement may be entered into before any substantive discussion. Unless otherwise agreed in writing, proposals received through this channel are considered non-confidential, and GenSight Biologics has no obligation of confidentiality, compensation or response.
7.3 Limited license. By sending us a comment or suggestion, you authorize us, on a non-exclusive and royalty-free basis, to use it to operate and improve our activities and the Site, without this amounting to an assignment of your intellectual property rights beyond that use, or to any obligation for GenSight Biologics to implement it. You warrant that you hold the necessary rights and that you are not infringing the rights of third parties.
7.4 No individual response to medical questions. GenSight Biologics cannot respond to requests for medical advice or individual guidance and invites you to consult your physician.
8. Rules of use of the Site
You undertake not to disrupt the operation of the Site or its servers, not to attempt to gain fraudulent access to non-public areas, not to introduce malicious software, and not to use bots, scrapers or other unauthorized automated tools, nor to carry out penetration tests without written authorization. To report a security vulnerability in good faith, write to infos@gensight-biologics.com.
9. Liability
9.1 Accuracy of information. GenSight Biologics endeavors to provide accurate and up-to-date information but cannot guarantee its accuracy, completeness or timeliness, in particular because scientific and clinical data evolve rapidly. GenSight Biologics is bound by an obligation of reasonable efforts (obligation de moyens) in this respect.
9.2 Availability. Access to the Site may be interrupted, for maintenance, and GenSight Biologics does not guarantee that the Site is free of errors or viruses. It is your responsibility to protect your equipment and data.
9.3 Limitation. To the extent permitted by law, GenSight Biologics is not liable for indirect damages resulting from the use of the Site or the inability to access it, nor for the use you make of the information on it. Nothing in these Terms excludes or limits the liability of GenSight Biologics in the event of fraud, gross negligence or personal injury, or where prohibited by law. The mandatory rights of consumers remain unaffected.
10. Changes to the Terms, governing law and contact
10.1 Changes to the Terms. GenSight Biologics may change the Terms at any time. The applicable version is the one published on the Site on the date of your visit, as indicated at the top of the document. We invite you to review them regularly.
10.2 Governing law and jurisdiction. The Terms are governed by French law. Subject to mandatory provisions, particularly those protecting consumers, any dispute relating to the Site falls within the exclusive jurisdiction of the French courts. These provisions do not deprive a consumer resident in the European Union of the rights conferred by the mandatory law of their country of residence, nor of the right to bring proceedings before the courts of that country. If any provision is held to be void or unenforceable, the remaining provisions shall remain in force.
10.3 Contact. For any question relating to these Terms: infos@gensight-biologics.com.
